Alisertib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alisertib" in English language version.

Last modified: 20:36:40, 2 March 2026 (UTC)

Ref.Un. Ref.Website

Global rank English rank

66nih.gov

5^th place

44doi.org

2^nd place

33worldcat.org

4^th place

33takeda.com

low place

11fiercebiotech.com

low place

6,413^th place

11pharmaphorum.com

low place

doi.org (Global: 2^nd place; English: 2^nd place)

Friedberg, JW; Mahadevan, D; Cebula, E; Persky, D; Lossos, I; Agarwal, AB; Jung, J; Burack, R; Zhou, X; Leonard, EJ; Fingert, H; Danaee, H; Bernstein, SH (Jan 1, 2014). "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas". Journal of Clinical Oncology. 32 (1): 44–50. doi:10.1200/JCO.2012.46.8793. PMC 3867644. PMID 24043741.
Manfredi, Mark G.; Ecsedy, Jeffrey A.; Chakravarty, Arijit; Silverman, Lee; Zhang, Mengkun; Hoar, Kara M.; Stroud, Stephen G.; Chen, Wei; Shinde, Vaishali; Huck, Jessica J.; Wysong, Deborah R.; Janowick, David A.; Hyer, Marc L.; Leroy, Patrick J.; Gershman, Rachel E. (2011-12-15). "Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays". Clinical Cancer Research. 17 (24): 7614–7624. doi:10.1158/1078-0432.CCR-11-1536. ISSN 1557-3265. PMID 22016509.
Niu, Huifeng; Manfredi, Mark; Ecsedy, Jeffrey A. (2015-08-24). "Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer". Frontiers in Oncology. 5: 189. doi:10.3389/fonc.2015.00189. ISSN 2234-943X. PMC 4547019. PMID 26380220.
Melichar, Bohuslav; Adenis, Antoine; Lockhart, A. Craig; Bennouna, Jaafar; Dees, E. Claire; Kayaleh, Omar; Obermannova, Radka; DeMichele, Angela; Zatloukal, Petr; Zhang, Bin; Ullmann, Claudio Dansky; Schusterbauer, Claudia (April 2015). "Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study". The Lancet. Oncology. 16 (4): 395–405. doi:10.1016/S1470-2045(15)70051-3. ISSN 1474-5488. PMID 25728526.

fiercebiotech.com (Global: low place; English: 6,413^th place)

Taylor, Nick Paul (September 21, 2022). "Puma pounces on failed Takeda drug, snapping up cancer prospect for knockdown price".

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Friedberg, JW; Mahadevan, D; Cebula, E; Persky, D; Lossos, I; Agarwal, AB; Jung, J; Burack, R; Zhou, X; Leonard, EJ; Fingert, H; Danaee, H; Bernstein, SH (Jan 1, 2014). "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas". Journal of Clinical Oncology. 32 (1): 44–50. doi:10.1200/JCO.2012.46.8793. PMC 3867644. PMID 24043741.
Manfredi, Mark G.; Ecsedy, Jeffrey A.; Chakravarty, Arijit; Silverman, Lee; Zhang, Mengkun; Hoar, Kara M.; Stroud, Stephen G.; Chen, Wei; Shinde, Vaishali; Huck, Jessica J.; Wysong, Deborah R.; Janowick, David A.; Hyer, Marc L.; Leroy, Patrick J.; Gershman, Rachel E. (2011-12-15). "Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays". Clinical Cancer Research. 17 (24): 7614–7624. doi:10.1158/1078-0432.CCR-11-1536. ISSN 1557-3265. PMID 22016509.
Niu, Huifeng; Manfredi, Mark; Ecsedy, Jeffrey A. (2015-08-24). "Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer". Frontiers in Oncology. 5: 189. doi:10.3389/fonc.2015.00189. ISSN 2234-943X. PMC 4547019. PMID 26380220.
Melichar, Bohuslav; Adenis, Antoine; Lockhart, A. Craig; Bennouna, Jaafar; Dees, E. Claire; Kayaleh, Omar; Obermannova, Radka; DeMichele, Angela; Zatloukal, Petr; Zhang, Bin; Ullmann, Claudio Dansky; Schusterbauer, Claudia (April 2015). "Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study". The Lancet. Oncology. 16 (4): 395–405. doi:10.1016/S1470-2045(15)70051-3. ISSN 1474-5488. PMID 25728526.

ncbi.nlm.nih.gov

Friedberg, JW; Mahadevan, D; Cebula, E; Persky, D; Lossos, I; Agarwal, AB; Jung, J; Burack, R; Zhou, X; Leonard, EJ; Fingert, H; Danaee, H; Bernstein, SH (Jan 1, 2014). "Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas". Journal of Clinical Oncology. 32 (1): 44–50. doi:10.1200/JCO.2012.46.8793. PMC 3867644. PMID 24043741.
Niu, Huifeng; Manfredi, Mark; Ecsedy, Jeffrey A. (2015-08-24). "Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer". Frontiers in Oncology. 5: 189. doi:10.3389/fonc.2015.00189. ISSN 2234-943X. PMC 4547019. PMID 26380220.

pharmaphorum.com (Global: low place; English: low place)

Taylor, Phil (September 21, 2022). "Takeda farms out cancer drug alisertib to Puma Biotech".

takeda.com (Global: low place; English: low place)

"Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma". Takeda Pharmaceutical Company Limited; Millennium Pharmaceuticals, Inc. March 6, 2012. Retrieved 20 March 2014.
"Research and Development Pipeline (As of February 5, 2014)" (PDF). Takeda Pharmaceutical Company Limited. February 5, 2014. p. 2. Retrieved 20 March 2014.
"Takeda Announces Termination of Alisertib Phase 3 Trial in Relapsed or Refractory Peripheral T-cell Lymphoma".

worldcat.org (Global: 4^th place; English: 4^th place)

search.worldcat.org

Manfredi, Mark G.; Ecsedy, Jeffrey A.; Chakravarty, Arijit; Silverman, Lee; Zhang, Mengkun; Hoar, Kara M.; Stroud, Stephen G.; Chen, Wei; Shinde, Vaishali; Huck, Jessica J.; Wysong, Deborah R.; Janowick, David A.; Hyer, Marc L.; Leroy, Patrick J.; Gershman, Rachel E. (2011-12-15). "Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays". Clinical Cancer Research. 17 (24): 7614–7624. doi:10.1158/1078-0432.CCR-11-1536. ISSN 1557-3265. PMID 22016509.
Niu, Huifeng; Manfredi, Mark; Ecsedy, Jeffrey A. (2015-08-24). "Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer". Frontiers in Oncology. 5: 189. doi:10.3389/fonc.2015.00189. ISSN 2234-943X. PMC 4547019. PMID 26380220.
Melichar, Bohuslav; Adenis, Antoine; Lockhart, A. Craig; Bennouna, Jaafar; Dees, E. Claire; Kayaleh, Omar; Obermannova, Radka; DeMichele, Angela; Zatloukal, Petr; Zhang, Bin; Ullmann, Claudio Dansky; Schusterbauer, Claudia (April 2015). "Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study". The Lancet. Oncology. 16 (4): 395–405. doi:10.1016/S1470-2045(15)70051-3. ISSN 1474-5488. PMID 25728526.

Alisertib (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

fiercebiotech.com (Global: low place; English: 6,413th place)

nih.gov (Global: 5th place; English: 5th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pharmaphorum.com (Global: low place; English: low place)

takeda.com (Global: low place; English: low place)

worldcat.org (Global: 4th place; English: 4th place)

search.worldcat.org

doi.org (Global: 2^nd place; English: 2^nd place)

fiercebiotech.com (Global: low place; English: 6,413^th place)

nih.gov (Global: 5^th place; English: 5^th place)

worldcat.org (Global: 4^th place; English: 4^th place)